Anti-NFkB p65 antibody (ab31407)

Overview

• Product nameAnti-NFkB p65 antibodySee all NFkB p65 primary antibodies ...
• Description
  Rabbit polyclonal to NFkB p65
• SpecificityAntibody detects endogenous levels of NFkB p65 protein around Threonine 435.
• Tested applicationsWB, ELISA, IHC-P more details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Mouse, Rat
• Immunogen

  Synthetic non-phosphopeptide derived from Human NFkB p65 around the phosphorylation site of Threonine 435.

• Positive controlBreast carcinoma tissue, extracts of COS7 cells treated with TNF alpha.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
• Concentration information loading...
• PurityImmunogen affinity purified
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Metabolism
  • Types of disease
  • Obesity

  • Cancer
  • Signal transduction
  • Nuclear signaling
  • NFkB pathway

  • Signal Transduction
  • Signaling Pathway
  • Nuclear Signaling
  • NFkB Pathway

  • Cardiovascular
  • Atherosclerosis
  • Vascular Inflammation
  • Inflammatory mediators

  • Microbiology
  • Interspecies Interaction
  • Host Virus Interaction

  • Microbiology
  • Interspecies Interaction
  • Host Immune Response

  • Epigenetics and Nuclear Signaling
  • Nuclear Signaling Pathways
  • NFkB pathway

  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Alzheimer's disease
  • Other

  • Cell Biology
  • Apoptosis
  • Intracellular
  • NFkB
  • RelA (p65)

Applications

Target

• FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.
• Sequence similaritiesContains 1 RHD (Rel-like) domain.
• Domainthe 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
• Post-translational
  modificationsUbiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.
  Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.
  Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity.
  Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of 'Lys-310'.
• Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction.

Target information above from: UniProt accession Q04206 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 5970 Human
  • Entrez Gene: 19697 Mouse
  • Entrez Gene: 309165 Rat
  • Omim: 164014 Human
  • SwissProt: Q04206 Human
  • SwissProt: Q04207 Mouse
  • Unigene: 502875 Human
  • Unigene: 249966 Mouse

  • Unigene: 19480 Rat

  see all

• Alternative names
  Avian reticuloendotheliosis viral (v rel) oncogene homolog A antibodyMGC131774 antibodyNF kappa B p65delta3 antibody

  NFKB 3 antibodyNFKB3 antibodyNFKB3 antibodyNuclear Factor NF Kappa B p65 Subunit antibodyNuclear factor NF-kappa-B p65 subunit antibodyNuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibodyNuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B Cells antibodyNuclear factor of kappa light polypeptide gene enhancer in B-cells 3 antibodyOTTHUMP00000233473 antibodyOTTHUMP00000233474 antibodyOTTHUMP00000233475 antibodyOTTHUMP00000233476 antibodyOTTHUMP00000233900 antibodyp65 antibodyp65 NF kappaB antibodyp65 NFkB antibodyRELA antibodyTF65_HUMAN antibodyTranscription Factor p65 antibodyv rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)) antibodyV Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A antibodyv rel reticuloendotheliosis viral oncogene homolog A (avian) antibodyV rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65 antibodyv-rel reticuloendotheliosis viral oncogene homolog A antibody

  see all

Anti-NFkB p65 antibody images

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - NFkB p65 antibody (ab31407)
  ab31407 at a 1:50-1:100 dilution staining NFkB p65 in human breast carcinoma using Immunohistochemistry, Paraffin Embedded Tissue.

  Left image : Un-treated.

  Right image : Antibody pre-incubated with synthesized peptide.

• 

  Western blot - NFkB p65 antibody (ab31407)
  All lanes : Anti-NFkB p65 antibody (ab31407) at 1/500 dilution
  
  Lane 1 : Extracts of COS7 cells (5-30ug) treated with TNF alpha.
  Lane 2 : Extracts of COS7 cells (5-30ug) treated with TNF alpha. Antibody pre-incubated with synthesized peptide.
  
  
  Predicted band size : 60 kDa